Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Arthritis & Rheumatology (Hoboken, N.J.)|December 19, 2022
Association of Circulating Antibody-Secreting Cell Maturity With Disease Features in Primary Sjögren's SyndromeTobit D Steinmetz, Gwenny M Verstappen, Sebastian R Schulz, et al.
Clinical and Experimental Rheumatology|December 27, 2023
Longitudinal evaluation of major salivary gland functioning in Sjögren's disease patients in a prospective standard-of-care cohortNiels R F Sluijpers, Konstantina Delli, Liseth De Wolff, et al.
Clinical and Experimental Rheumatology|December 10, 2024
Field testing and clinical validation of the mSQUASH to measure physical activity in patients with Sjögren's diseaseNoa S Ausma, Yvonne M van der Kraan, Liseth de Wolff, et al.
Clinical and Experimental Rheumatology|December 19, 2024
Abatacept use for 24 weeks has a limited effect on salivary gland inflammation in Sjögren's disease patientsUzma Nakshbandi, Silvia C Liefers, Suzanne Arends, et al.
Clinical and Experimental Rheumatology|November 28, 2022
Patient Acceptable Symptom State (PASS) in patients with primary Sjögren's syndrome in daily clinical practiceLiseth de Wolff, Arjan Vissink, Jolien F van Nimwegen, et al.
RMD Open|April 13, 2022
Immunogenicity and safety of COVID-19 vaccination in patients with primary Sjögren's syndromeGwenny M Verstappen, Liseth de Wolff, Suzanne Arends, et al.
Clinical and Experimental Rheumatology|November 19, 2021
Differences in presentation between paediatric- and adult-onset primary Sjögren's syndrome patientsGeertje E Legger, Margit B Erdtsieck, Liseth de Wolff, et al.
Seminars in Arthritis and Rheumatism|March 26, 2026
Sex differences in patient-reported outcome measures and clinical parameters in patients with Sjögren's diseaseHelene Kokol, Dagmar Rebel, Liseth de Wolff, et al.
Seminars in Arthritis and Rheumatism|January 29, 2022
Long-term abatacept treatment for 48 weeks in patients with primary Sjögren's syndrome: The open-label extension phase of the ASAP-III trialLiseth de Wolff, Jolien F van Nimwegen, Esther Mossel, et al.
The Lancet. Rheumatology|January 30, 2024
Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measureSuzanne Arends, Liseth de Wolff, Jolien F van Nimwegen, et al.
Pageof 3